CIK 0001642380
- Non-accelerated filer
- Smaller reporting company
Insight Molecular Diagnostics Inc.
Sign in to watch- Ticker
- IMDX
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 271041563
- Phone
- +1 949-409-7600
- Business address
- 2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
- Former names
- OncoCyte Corp, Oncocyte Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 23 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-11 | Levine Mitchell S CFO | Grant or award | +10,121 | 46,700 | ||
| 2020-09-12 | Levine Mitchell S CFO | Purchase | +10,000 | $2.01 | $20K | 13,495 |
| 2020-08-03 | Parker Albert P Chief Operating Officer | Purchase | +5,000 | $1.33 | $7K | 5,000 |
| 2020-08-03 | KALAJIAN TONY T Sr.VP/Chief Accounting Officer | Purchase | +5,000 | $1.31 | $7K | 15,000 |
| 2020-08-03 | ANDREWS RONALD ASBURY Chief Executive Officer | Purchase | +40,000 | $1.35 | $54K | 102,698 |
| 2020-08-03 | Levine Mitchell S Chief Financial Officer | Purchase | +10,000 | $1.32 | $13K | 36,579 |
| 2020-06-17 | Redmond Cavan M. Director | Grant or award · Option to purchase common stock | +62,000 | 62,000 | ||
| 2020-06-17 | GRIFFITH MELINDA Director | Grant or award · Option to purchase common stock | +57,000 | 57,000 | ||
| 2020-06-17 | Last Andrew J. Director | Grant or award · Option to purchase common stock | +57,000 | 57,000 | ||
| 2020-06-17 | KINGSLEY ALFRED D Director | Grant or award · Option to purchase common stock | +57,000 | 57,000 | ||
| 2020-06-17 | Arno Andrew Director | Grant or award · Option to purchase common stock | +57,000 | 57,000 | ||
| 2020-05-07 | ANDREWS RONALD ASBURY Chief Executive Officer | Grant or award · Restricted Stock Units | +106,221 | 106,221 | ||
| 2020-04-28 | Levine Mitchell S Chief Financial Officer | Grant or award · Restricted Stock Units | +20,000 | 20,000 | ||
| 2020-04-28 | Levine Mitchell S Chief Financial Officer | Grant or award · Restricted Stock Units | −20,000 | 20,000 | ||
| 2020-04-24 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | +1,050,000 | $2.27 | $2.4M | 14,716,204 |
| 2020-04-24 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | +0 | 14,716,204 | ||
| 2020-03-31 | ANDREWS RONALD ASBURY CEO and President | Purchase | +18,000 | $2.37 | $43K | 62,698 |
| 2020-03-31 | ANDREWS RONALD ASBURY CEO and President | Purchase | +18,000 | $2,372.00 | $42.7M | 62,698 |
| 2020-03-30 | ANDREWS RONALD ASBURY CEO and President | Purchase | +27,216 | $2.26 | $61K | 44,698 |
| 2020-03-30 | ANDREWS RONALD ASBURY CEO and President | Purchase | +27,216 | $2.26 | $61K | 44,698 |
Page 16 of 20 · 383 trades